Welcome to our dedicated page for Quidel SEC filings (Ticker: QDEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rapid diagnostic manufacturers like QuidelOrtho pack hundreds of pages with data on FDA approvals, respiratory test demand, and global reagent sales. Parsing those details—and catching when executives sell stock just before a new assay launch—takes time most professionals don’t have. That’s why our SEC page starts where the paperwork ends: delivering QuidelOrtho SEC filings explained simply.
Stock Titan’s AI reads every 10-K, 10-Q, 8-K, and DEF 14A the moment it hits EDGAR, then surfaces what matters. Want the QuidelOrtho quarterly earnings report 10-Q filing without wading through accounting footnotes? Our AI summary highlights respiratory segment margins in seconds. Need QuidelOrtho insider trading Form 4 transactions? Real-time alerts flag every submission, letting you monitor QuidelOrtho executive stock transactions Form 4 before the market reacts. Each filing card links to plain-language explanations—perfect for understanding QuidelOrtho SEC documents with AI.
Beyond form codes, we connect disclosures to questions analysts really ask. The annual report 10-K simplified shows how immunoassay revenue compares to molecular diagnostics, while our QuidelOrtho earnings report filing analysis maps R&D spending to upcoming test launches. The latest QuidelOrtho proxy statement executive compensation reveals how bonuses hinge on regulatory clearances, and our AI notes any red flags. Even sudden supply-chain updates arrive via QuidelOrtho 8-K material events explained. With comprehensive coverage, AI-powered summaries, and Form 4 insider transactions in real time, this page turns dense disclosures into actionable insight—so you can focus on decisions, not document hunting.
Rubric Capital Management LP and its managing member David Rosen filed Amendment No. 2 to Schedule 13G disclosing a 6.86 % passive stake in QuidelOrtho Corporation (QDEL) as of 30 June 2025.
The filing covers 4,637,738 common shares, all held with shared voting and dispositive power; neither party claims sole authority over the stock. The position is reported on the basis of 67,625,872 shares outstanding (per QDEL’s 30 March 2025 Form 10-Q). Rubric acts as investment adviser to a series of funds, the largest of which—Rubric Capital Master Fund LP—has the economic right to dividends or sale proceeds exceeding 5 % of QDEL’s shares.
The Schedule 13G is filed under Rule 13d-1(b), signalling a passive investment with no intent to influence control of the issuer. Both reporting persons certify that the shares were acquired in the ordinary course of business and not for activist purposes.
Key ownership details:
- Sole voting/dispositive power: 0 shares
- Shared voting/dispositive power: 4,637,738 shares
- Percent of class: 6.86 %
The amendment updates Rubric’s aggregate holdings but does not announce any purchase or sale terms, financing arrangements, or governance initiatives. Consequently, the disclosure is largely informational, indicating Rubric has crossed—and continues to hold—above the 5 % reporting threshold.
SEC Form 4 filed for First Guaranty Bancshares, Inc. (FGBI) discloses that director Edgar R. Smith III markedly increased his ownership on 30 June 2025.
- Open-market purchase: 30,865 common shares acquired at $8.10 (Code P).
- Debt-for-equity exchange: 1,981,506 new shares issued at $7.57 in exchange for a $15 million floating-rate subordinated note under an Exchange Agreement dated 16 June 2025.
- Note amendments: 88,482 shares issued at $8.00 to Smith & Tate Investments, LLC pursuant to amendments to an existing promissory note and a subordinated note.
Following these transactions, Smith reports 2,852,467 shares held directly. Indirectly, he controls additional positions through several LLCs, including Smith & Hood Holding Company, LLC (1,062,817 shares) and three other investment entities, taking total reported beneficial ownership well above three million shares.
The filing signals a net addition of roughly 2.1 million shares, replacing interest-bearing debt with equity and reflecting continued insider confidence. Because the new shares were issued below recent market purchases ($7.57 vs. $8.10), the company reduces debt at a valuation apparently acceptable to both parties while the director deepens alignment with common shareholders.
Form 4 filing for UnitedHealth Group (UNH) dated 07/02/2025 discloses routine quarterly equity compensation to non-employee director Paul R. Garcia.
- Transactions (07/01/2025): 173 deferred stock units (immediately vested, must be held until board service ends) and 96 shares of common stock, both awarded at $0 cost.
- Post-transaction ownership: 2,750 common shares held directly; 2,146 shares in a revocable trust; 45 and 55 shares in two additional trusts, for a total indirect holding of 2,246 shares.
- No derivative securities were acquired or disposed of; the filing cites the awards as regular quarterly director compensation, not incentive-based or market purchases.
The filing is administrative in nature, with no impact on company operations, capital structure, or insider sentiment beyond customary board compensation.
MGIC Investment Corp. (MTG) – Form 4 insider transaction
President & COO Salvatore A. Miosi disclosed the sale of 30,000 shares of common stock on 01-Jul-2025 at a weighted-average price of $28.152 per share, generating roughly $0.84 million in proceeds. The disposition was executed under a Rule 10b5-1 trading plan adopted on 06-Mar-2025, indicating the sale was pre-scheduled and not necessarily driven by near-term information.
After the transaction, Miosi directly owns 279,401.361 shares and indirectly controls 384,844 shares via a family trust, maintaining a sizable equity stake. No derivative security activity was reported, and the filing contains no references to earnings, major corporate events, or strategic changes.
The filing primarily records a routine adjustment to the executive’s equity exposure; in isolation, it is unlikely to materially affect the company’s fundamental outlook.
FAQ
What is the current stock price of Quidel (QDEL)?
What is the market cap of Quidel (QDEL)?
What is the core business of QuidelOrtho Corporation?
Which healthcare segments does QuidelOrtho serve?
How does QuidelOrtho generate its revenue?
What differentiates QuidelOrtho from other diagnostic manufacturers?
Where does QuidelOrtho have a global presence?
What role does innovation play in QuidelOrtho's business model?
How does QuidelOrtho contribute to clinical decision-making?
What are some common applications of QuidelOrtho's diagnostic tests?
